Biocryst Pharmaceuticals (BCRX) Change in Receivables (2010 - 2026)

Biocryst Pharmaceuticals has reported Change in Receivables for 17 years, with the latest figure at $474000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 96.61% year-over-year to $474000.0; the trailing twelve-month figure through Mar 2026 stood at $23.3 million (down 29.08% YoY), and the FY2025 full-year result was $36.8 million, up 62.16% from the prior year.
• Change in Receivables for Q1 2026 stood at $474000.0, down from $15.5 million in the prior quarter.
• The five-year high for Change in Receivables was $15.5 million in Q4 2025, with the low at -$3.8 million in Q3 2023.
• Historically, Change in Receivables has averaged $5.1 million across 5 years, with a median of $5.3 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Receivables surged 2600.38% — and 2023, when it tumbled 358.96%.
• Biocryst Pharmaceuticals' Change in Receivables stood at $7.6 million in 2022, then sank by 61.14% to $3.0 million in 2023, then soared by 145.66% to $7.3 million in 2024, then soared by 112.36% to $15.5 million in 2025, then sank by 96.94% to $474000.0 in 2026.
• The last three Change in Receivables figures came in at $474000.0 (Q1 2026), $15.5 million (Q4 2025), and $17000.0 (Q3 2025), per Business Quant data.